Pfizer (PFE) Stock Looks Attractive for Income Investors
Pfizer ($PFE) stock looks attractive for income investors because of its well-covered dividend and modest valuation. The drug maker’s shares have o...
Pfizer Inc (PFE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 112,118,836 | $3,197,629,222 | +3% | 0.92% |
| 2. | Pzena Investment Management Richard S. Pzena | 6,050,227 | $172,552,474 | +2% | 0.51% |
| 3. | Leucadia National Ian Cumming And Joseph Steinberg | 792,649 | $22,606,350 | +24% | 0.17% |
| 4. | Bourgeon Capital John Zaro | 373,919 | $10,664,170 | +1% | 1.53% |
| 5. | Hourglass Capital Kenneth A. Moffet | 344,398 | $9,822,231 | -4% | 2.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $26.34 | 38,000 | $1,000,920.00 | 429,173 | 2026-08-12 | Filing | |
| $25.46 | 39,231 | $998,821.26 | 66,938 | 2026-08-05 | Filing | |
| $25.52 | 37,632 | $960,368.64 | 37,632 | 2026-08-05 | Filing | |
| $25.65 | 19,457 | $499,072.05 | 27,707 | 2025-02-13 | Filing | |
| $28.24 | 1,000 | $28,240.00 | 10,000 | 2024-10-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.40 | 3,278 | $83,261.20 | 28,611 | 2026-08-05 | Filing | |
| $25.70 | 2,000 | $51,400.00 | 31,397 | 2026-06-09 | Filing | |
| $25.93 | 2,500 | $64,825.00 | 11,850 | 2025-03-04 | Filing | |
| $28.66 | 5,154 | $147,713.64 | 8,582 | 2024-08-13 | Filing | |
| $40.02 | 9,912 | $396,678.24 | 9,003 | 2023-03-15 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 137,506,393 | $3,907,781,638 | 0.2% | |
| 2. | 46,935,508 | $1,338,603,644 | 0.27% | |
| 3. | 45,383,634 | $1,294,341,247 | 0.21% | |
| 4. | 38,525,161 | $1,098,803,601 | 0.2% | |
| 5. | 32,510,872 | $927,210,069 | 0.26% |
News See All
Pfizer (PFE) vs. AstraZeneca (AZN): Which Pharma Stock Offers a Better Dividend?
Pfizer ($PFE) and AstraZeneca ($AZN) are two pharmaceutical companies that offer dividends. Both offer dividend yields above the broader market, bu...
Pfizer Stock (PFE) Flat Despite Q3 Beat and Raised 2026 Sales Outlook — Here’s Why
Pfizer shares ($PFE) traded flat in Tuesday’s pre-market session even after the U.S. pharma giant beat Q3 earnings expectations and raised its 2026...
Options Volatility and Implied Earnings Moves Today, November 03, 2026
Today, several major companies are expected to report earnings: Advanced Micro Devices (AMD), Amgen (AMGN), Energy Transfer (ET), Pfizer (PFE), Sup...
Pfizer (PFE) Reports Q3 Earnings Tomorrow — Here’s Why Wall Street Remains Split
U.S. pharma giant Pfizer ($PFE) is set to release its third-quarter 2026 earnings tomorrow, November 3, before the market opens. Despite pressure o...
Options Volatility and Implied Earnings Moves This Week, November 02 – November 06, 2026
This week, several major companies will be reporting earnings. Among them are Apple (AAPL), Palantir Technologies (PLTR), Advanced Micro Devices (A...
The Week That Was, The Week Ahead: Macro and Markets, November 1
U.S. stocks ended Friday sharply lower as disappointing technology earnings and concerns over massive AI spending sent Wall Street into another sel...
Pfizer (PFE) Lung Cancer Drug Shows Survival Benefit Despite Trial Failure
Pfizer ($PFE) is keeping its experimental lung cancer drug alive despite a failed clinical trial. New data showed that some patients treated with s...
Moderna (MRNA) vs. BioNTech (BNTX): Which Biotech Stock Offers Upside, According to Wall Street?
Moderna ($MRNA) and BioNTech ($BNTX) are biotech stocks focused on cancer vaccines as they enter their next growth phase. According to TipRanks Com...
11 Best Cancer Stocks to Invest In Now
Cancer’s Burden Keeps the Search for Better Treatments Urgent For cancer patients, progress means more time, fewer side effects, and a better chance of recovery.
Hedge Fund Resource Center